Beyond genetics in personalized cancer treatment: Assessing dynamics and heterogeneity of tumor responses

Personalized Medicine

Volumn 10, Issue 3, 2013, Pages 221-225

  Tyson, Darren R ^a   Quaranta, Vito ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer therapeutics; dynamic treatment response; single cell analysis; tumor heterogeneity

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1;

CANCER GENETICS; CANCER RESISTANCE; CANCER THERAPY; CELL DEATH; CELL DIVISION; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; EX VIVO STUDY; GENE AMPLIFICATION; GENE MUTATION; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SYSTEMS BIOLOGY; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH;

EID: 84877616844     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.6     Document Type: Review

References (40)

1. von Hansemann DP. [Asymmetric cell division in epithelial cancers and its biological significance]. Virchows Archiv 119(2), 299-326 (1890).
2. Rous PP. A transmissible avian neoplasm. (Sarcoma of the common fowl) by Peyton Rous, M.D., Experimental Medicine for Sept. 1, 1910, vol. 12, pp.696-705. J. Exp. Med. 12(5), 696-705 (1910).
3. Martin GS. Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature 227(5262), 1021-1023 (1970).
4. Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260(5547), 170-173 (1976).
5. Oppermann H, Levinson AD, Varmus HE, Levintow L, Bishop JM. Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (Src). Proc. Natl Acad. Sci. USA 76(4), 1804-1808 (1979).
6. Spector DH, Varmus HE, Bishop JM. Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates. Proc. Natl Acad. Sci. USA 75(9), 4102-4106 (1978).
7. Witte ON, Dasgupta A, Baltimore D. Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature 283(5750), 826-831 (1980).
8. Ushiro H, Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 255(18), 8363-8365 (1980).
9. Downward J, Yarden Y, Mayes E et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307(5951), 521-527 (1984).
10. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002).
11. Garber ME, Troyanskaya OG, Schluens K et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98(24), 13784-13789 (2001).
12. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
13. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344(14), 1031-1037 (2001).
14. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
15. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
16. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
17. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297(5578), 63-64 (2002).
18. Felsher DW. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res. 68(9), 3081-3086; discussion 3086 (2008).
19. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005).
20. Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29(22), 3085-3096 (2011).
21. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
22. Blakely CM, Bivona TG. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov. 2(10), 872-875 (2012).
23. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
24. Yancovitz M, Litterman A, Yoon J et al. Intra-and inter-tumor heterogeneity of BRAFV600E mutations in primary and metastatic melanoma. PLoS ONE 7(1), e29336 (2012).
25. Barretina J, Caponigro G, Stransky N et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391), 603-607 (2012).
26. Tyson DR, Garbett SP, Frick PL, Quaranta V. Fractional proliferation: a method to deconvolve cell population dynamics from single-cell data. Nat. Methods 9(9), 923-928 (2012).
27. Quaranta V, Tyson DR, Garbett SP, Weidow B, Harris MP, Georgescu W. Trait variability of cancer cells quantified by high-content automated microscopy of single cells. Meth. Enzymol. 467, 23-57 (2009).
28. Janes KA, Albeck JG, Gaudet S, Sorger PK, Lauffenburger DA, Yaffe MB. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 310(5754), 1646-1653 (2005).
29. Albeck JG, Burke JM, Spencer SL, Lauffenburger DA, Sorger PK. Modeling a snap-action, variable-delay switch controlling extrinsic cell death. PLoS Biol. 6(12), 2831-2852 (2008).
30. Slack MD, Martinez ED, Wu LF, Altschuler SJ. Characterizing heterogeneous cellular responses to perturbations. Proc. Natl Acad. Sci. USA 105(49), 19306-19311 (2008).
31. Gascoigne KE, Taylor SS. Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14(2), 111-122 (2008).
32. Atuegwu NC, Arlinghaus LR, Li X et al. Integration of diffusion-weighted MRI data and a simple mathematical model to predict breast tumor cellularity during neoadjuvant chemotherapy. Magn. Reson. Med. 66(6), 1689-1696 (2011).
33. Zhao B, Oxnard GR, Moskowitz CS et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin. Cancer Res. 16(18), 4647-4653 (2010).
34. Tentner AR, Lee MJ, Ostheimer GJ, Samson LD, Lauffenburger DA, Yaffe MB. Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol. Syst. Biol. 8, 568 (2012).
35. Kreeger PK, Lauffenburger DA. Cancer systems biology: a network modeling perspective. Carcinogenesis 31(1), 2-8 (2010).
36. Vicini P. Multiscale modeling in drug discovery and development: future opportunities and present challenges. Clin. Pharmacol. Ther. 88(1), 126-129 (2010).
37. Anderson ARA, Quaranta V. Integrative mathematical oncology. Nat. Rev. Cancer 8(3), 227-234 (2008).
38. Quaranta V, Weaver AM, Cummings PT, Anderson AR. Mathematical modeling of cancer: the future of prognosis and treatment. Clin. Chim. Acta 357(2), 173-179 (2005).
39. Atuegwu NC, Colvin DC, Loveless ME, Xu L, Gore JC, Yankeelov TE. Incorporation of diffusion-weighted magnetic resonance imaging data into a simple mathematical model of tumor growth. Phys. Med. Biol. 57(1), 225-240 (2011).
40. The Nobel Prize in Physiology or Medicine 1958. www.nobelprize.org/nobel- prizes/medicine/laureates/1958